Search Results
Jun 03, 2026, 00:04 ET Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
2026.8 Kawka L, et al. Fatigue in Systemic Lupus Erythematosus: An Update on Its Impact, Determinants and Therapeutic Management. J Clin Med. 2021 Sep 3;10(17):3996. doi: 10.3390/jcm10173996. PMID: 34501444; PMCID: PMC8432566.9 Guéry JC. Why Is Systemic Lupus Erythematosus
More news about: Johnson & Johnson
Jun 03, 2026, 00:03 ET Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
10.1038/s41584-023-01057-6.7 Meudec L, Nocturne G, Mariette X. Update on the Aetiopathogenesis of Sjögren Disease: From Interferon Signaling to Epithelial Dysfunction. J Clin Med. 2026 Mar 4;15(5):1945. doi: 10.3390/jcm150519458 Mayo Clinic. Sjogren's syndrome. Available at:
More news about: Johnson & Johnson
Jun 02, 2026, 20:24 ET Hydreight Announces Refiling of Interim Financial Statements
directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians and other licensed healthcare professionals. The Hydreight platform allows healthcare professionals to deliver services independently,
More news about: Hydreight Technologies Inc.
Jun 02, 2026, 14:18 ET The Inner Circle acknowledges Ashley "Ash" Spoto, M.Ed as a Pinnacle Professional of The Year
multimedia:https://www.prnewswire.com/news-releases/the-inner-circle-acknowledges-ashley-ash-spoto-med-as-a-pinnacle-professional-of-the-year-302788897.htmlSOURCE
More news about: The Inner Circle
Jun 02, 2026, 13:00 ET Alani Skin MD Named "Best Med Spa" in 2026 Best of the Desert Community's Choice Awards
SCOTTSDALE, Ariz., June 2, 2026 /PRNewswire/ -- Alani Skin MD has been named "Best Med Spa" in the 2026 Best of the Desert Community's Choice Awards, a voter-driven program recognizing standout businesses and service providers across Arizona.
More news about: Alani Skin MD
Jun 02, 2026, 11:00 ET Fingerpaint Group Names Sarah Cherng as Chief Technology & Product Officer Role
GroupFingerpaint Group is an award-winning, top 20 healthcare agency and a unified commercialization platform for the life sciences, named Med Ad News Network of the Year in 2026. Partnering with 95% of the top 20 global pharmaceutical companies, Fingerpaint Group combines imagination with innovation
More news about: Fingerpaint Group
Jun 02, 2026, 08:38 ET Predictive Ballistics Selected as Primary Supplier of Overt Armor Kit (OAK) by Federal Bureau of Investigation (FBI)
offers a number of recognized brand names in these markets including Safariland® Armor, Duty Gear and Communications, Bianchi®, Break Free®, Hatch®, Med-Eng®, Identicator® and NIK®. The Safariland Group's mission, "Together, We Save Lives®," is inherent in the lifesaving and protective products it delivers.
More news about: Predictive Ballistics
Jun 02, 2026, 03:00 ET Yozma tillkännager Landmark Football Partnership inför sitt ettårsjubileum
ettårsjubileumskampanj tillsammans med sitt banbrytande partnerskap med de belgiska Red Devils, går Yozma in i ett nytt kapitel av global tillväxt, kulturell relevans och expansion inom outdoor-livsstil.Fira med YozmaYozmas ettårsjubileumskampanj är nu live, med exklusiva kampanjer, community-evenemang
More news about: Yozmasports
Jun 01, 2026, 21:32 ET Hydreight Delivers Record First Quarter 2026 Revenue of $24.9 Million with 449% Revenue Growth, $3.3 Million in Adjusted EBITDA² and $32.0 Million in Working Capital
directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed healthcare professionals. The Hydreight platform allows healthcare professionals to deliver services independently,
More news about: Hydreight Technologies Inc.
Jun 01, 2026, 16:00 ET EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
(investors) REFERENCESMountzios G, Sun L, Cho BC, et al. Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N Engl J Med. 2025;393(4):349-361.Amgen. (2026) Imdylltra 1 mg and 10 mg powder for concentrate and solution for infusion: Summary of product characteristics.
More news about: Amgen
Jun 01, 2026, 11:11 ET UCB Launches Career-Advancing Scholarship Program for Adults Living with Hidradenitis Suppurativa and Immediate Family Members
al. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18.Jemec GBE. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158–64.Date of preparation: May 2026©2026 UCB, Inc., Smyrna, GA 30080. All rights reserved.UCB
More news about: UCB
Jun 01, 2026, 09:01 ET Veritas Aortic Solutions, an inQB8 Spinout, Raises $12M to Advance Non-Surgical Treatment of Aortic Root and Ascending Aortic Diseases
(CSIPCo)Cedars-Sinai Intellectual Property Company is the investment arm of Cedars-Sinai, focused on healthcare and life sciences startups across med tech (devices & diagnostics), biotech (drug discovery programs) and health tech (regulated digital health). CSIPCo invests in companies that strongly
More news about: Veritas Aortic Solutions
Jun 01, 2026, 09:00 ET Millions of Women Go Through Menopause. Research Hasn't Kept Up.
understood, studied, and treated."A National Program for Emerging Women's Health ResearchersThe Winona Research Initiative welcomes pre-med and medical students, OB-GYN residents, fellows, and early faculty with an interest in women's health research, particularly menopause. Applicants should
More news about: Winona
Jun 01, 2026, 04:19 ET Sobi to present new data on pegcetacoplan at ERA 2026
Tarragón, B, et al. Clin J Am Soc Nephrol 2024; 19(8)1005-1015.5. Data on file using literature consensus.6. Fakhouri F, et al. N Engl J Med 2025;393:2210-2220CONTACT: Visiting addressNorra Stationsgatan 93A, Stockholm+46 8 697 20 00
More news about: Swedish Orphan Biotrauma AB
Jun 01, 2026, 03:04 ET China's Original Innovative Drug Cipepofol Approved for Marketing by the U.S. FDA
safety of ciprofol sedation in ICU patients undergoing mechanical ventilation: A multicenter, single-blind, randomized, noninferiority trial. Crit Care Med. 2023;8.3(IF).Liu YJ, Zuo LY, Li XY, et al. Early sedation using ciprofol for intensive care unit patients requiring mechanical ventilation:
More news about: Haisco
May 31, 2026, 20:15 ET Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
contained in this press release.References[1] Qi C, et al. ASCO 2026. 2026 Jun; Poster #2557[2] Qi C, et al. Nat Med (2024). DOI: 10.1038/s41591-024-03037-z2[3] Qi C, et al. ASCO 2024. 2024 Jun; Oral presentation #2501For
More news about: CARsgen Therapeutics
May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
2026.13 Barsouk A, Aluru JS, Rawla P, Saginala K, Barsouk A. Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. Med Sci (Basel). 2023;11(2):42. Published 2023 Jun 13. doi:10.3390/medsci1102004214 Ghiani L, Chiocca S. High Risk-Human Papillomavirus
More news about: Johnson & Johnson
May 31, 2026, 08:27 ET Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
2026; Chicago.2 Taplin ME, Gleave M, Shore ND, et al. Perioperative Apalutamide in High-Risk Localized Prostate Cancer. N Engl J Med. 2026. doi:10.1056/NEJMoa2603878.3 Young HH. The early diagnosis and radical cure of carcinoma of the prostate. Being a study of
More news about: Johnson & Johnson
May 29, 2026, 17:06 ET Die Menarini Group präsentiert auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO) neue Daten aus der Phase-1b/2-Studie ELEVATE zu Elacestrant in Kombination mit Capivasertib bei Patientinnen mit ER-positivem, HER2-negativem metastasiertem Brustkrebs (mBC)
metastasiertem Brustkrebs mit Veränderungen im PI3K-Signalweg decken, insbesondere wenn gleichzeitig ESR1- und PIK3CA-Mutationen vorliegen", erklärte Dr. med. Sara Tolaney, MPH, Leiterin der Abteilung für Brustonkologie am Dana-Farber Cancer Institute. „Diese vielversprechenden vorläufigen Daten deuten auf
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 09:33 ET Novo Nordisk amplia acesso à semaglutida biológica com preços até 50% mais baixos para tratamento de obesidade e diabetes no Brasil
and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221-2232. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. N Engl J Med. doi:10.1056/NEJMoa2413258 Arnaut T, Kazantseva K, Kvist
More news about: Novo Nordisk
May 29, 2026, 08:42 ET Outcomes Rocket CEO Recognized with 2026 Healthcare Marketer of the Year Award by Swaay.Health
outcomesrocket.comAbout Outcomes RocketOutcomes Rocket is a market research, advisory, and marketing execution agency focused on helping med-tech and health-tech companies grow. The firm partners with innovators across medical devices, digital health, and health IT to build commercial momentum
More news about: Outcomes Rocket
May 29, 2026, 08:00 ET AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
2026.4Brown JR, Seymour JF, Jurczak W, et al. Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. N Engl J Med. 2025;392(8):748-762.
More news about: AbbVie
May 29, 2026, 08:00 ET AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
2026.4Brown JR, Seymour JF, Jurczak W, et al. Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. N Engl J Med. 2025;392(8):748-762.
More news about: AbbVie
May 29, 2026, 07:01 ET SHINE Secures European Marketing Authorization for Ilumira, Latest Step in Building Integrated Nuclear Medicine Platform
radioisotopes-in-medicine[2] Niu T, Fan M, Lin B, et al. Current clinical application of lutetium-177 in solid tumors (Review). Exp Ther Med. 2024;27(5):225. doi:10.3892/etm.2024.12514. PMID: 38596660; PMCID: PMC11002837. Accessed April 30, 2026.
More news about: SHINE Technologies, LLC
May 28, 2026, 21:12 ET Wellness Technology Distributor Helping People Set Up Wellness Center Businesses
business around it. USA Med Bed's model provides both the equipment and the operational support framework, giving entrepreneurs a more complete path from concept to open doors.About USA Med BedUSA Med Bed is a wellness
More news about: USA Med Bed, LLC